Study guide
7.3 Quality Control, Product Verification, and Release Testing
PTCB Nonsterile Compounding Certificate Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Regulations, Standards, and Governance
1.1 Federal Regulations Framework (FD&C Act, DQSA, Sections 503A vs 503B) 1.2 USP Standards & Applicability (<795>, <800>, <1163>) 1.3 Personnel Roles, Training, and Hygiene Standards 1.4 Documentation, Master Formulation Records, and Compounding Records
2 Chapter 2: Facilities, Material Management, and Stability
2.1 Facilities, Environmental Controls, and Equipment 2.2 Material Sourcing, Component Selection & Inventory Controls 2.3 Beyond-Use Dates (BUDs), Stability & Packaging
3 Chapter 3: Nonsterile Dosage Forms & Formulations
3.1 Solid Dosage Forms & Compounding 3.2 Semisolid Dosage Forms 3.3 Liquid Dosage Forms 3.4 Specialized Topical & Transdermal Formulations
4 Chapter 4: Equipment, Utensils, and Processing Tools
4.1 Weighing and Volumetric Equipment 4.2 Mixing and Comminution Utensils
5 Chapter 5: Pharmaceutical Compounding Calculations
5.1 Weighing, Measuring, Aliquot Calculations, & Powder Volume Adjustments 5.2 Concentration, Alligation, Dilution, & Dosing Calculations
6 Chapter 6: Compounding Procedures, Garbing, and Hazardous Drug Safety
6.1 Garbing, Hand Hygiene, and Personal Protective Equipment for Nonsterile Compounding 6.2 Hazardous Drug Handling and USP <800> Compliance in Nonsterile Compounding 6.3 Packaging, Container-Closure Systems, Storage, and Quality Assurance
7 Chapter 7: Quality Assurance, Sanitation, and Risk Management
7.1 Cleaning, Sanitizing, and Facility Sanitation Protocols 7.2 Environmental Monitoring, Equipment Calibration, and Maintenance 7.3 Quality Control, Product Verification, and Release Testing 7.4 Quality Assurance Systems, Customer Complaints, and Product Recalls
7.3 Quality Control, Product Verification, and Release Testing
Key Takeaways Explain This Topic AI
Release requires physical inspection, traceability, documentation review, correct packaging and labeling, and every formulation-specific test required by the MFR, monograph, SOP, and law.
Weight-variation sample plans and limits are formulation-specific; a blanket 10-unit ±10%/±15% rule is not universal, and weight does not directly prove potency.
Percent yield = actual/theoretical × 100; acceptability comes from the approved process specification, not a universal 95–105% rule.
USP <795> uses 90–110% of labeled strength as the general CNSP expectation unless an applicable monograph or formulation specification is different.
A deviation or unexplained result triggers quarantine, documented impact assessment, root-cause investigation when appropriate, and authorized disposition before release.
Last updated: August 2026
7.3 Quality Control, Product Verification, and Release Testing
Quick Answer: A CNSP is released only after it meets the specifications in its master formulation, applicable monograph, SOPs, and law. Every preparation receives appropriate physical inspection and documentation review; additional weight, pH, yield, potency, or microbial tests are used when the formulation and risk require them. Do not apply a universal ±10% capsule rule or 95–105% yield rule to every CNSP.
QA and QC
Quality assurance (QA) designs and monitors the system: SOPs, training, supplier qualification, equipment control, deviation review, and continual improvement. Quality control (QC) is product-focused: observations, measurements, tests, and documentation used to decide whether a specific preparation meets its specification. QC is planned, not merely “reactive.”
Technicians may perform or document authorized checks, but final verification and release authority follow state law, scope of practice, and facility policy.
Universal Release Questions
Before release, confirm:
Identity and traceability: Correct prescription, patient, drug form, strength, component lots, and quantities.
Process: The approved master formulation was followed and deviations were resolved.
Appearance: Color, odor, texture, clarity, redispersibility, fill, and absence of foreign matter match the specification.
Container and label: Packaging is compatible and intact; route, directions, storage, auxiliary labels, and BUD are correct.
Quantity and reconciliation: Actual yield or count is documented and any unexplained loss or gain is investigated.
Authorization: Required checks and signatures are complete.
A failed or unexplained result triggers quarantine. Do not “average away” an outlier or rework a preparation without an approved investigation and procedure.
- Dosage-Form Checks
- Solutions and Suspensions
A solution expected to be clear should have no unexpected cloudiness, precipitate, color change, or foreign material. A suspension should redisperse as the master formulation specifies, without hard caking, and its container must permit adequate shaking. pH, density, or assay is measured when the formulation specifies it.
Emulsions and Semisolids
Inspect for homogeneity, smoothness, air entrapment, unexpected crystals, leakage, and phase separation. Reversible creaming differs from cracking/breaking , an irreversible separation of the emulsion. A cracked product is quarantined and investigated rather than casually remixed.
Capsules and Molded Units
Inspect shell closure, cleanliness, damage, fill consistency, and count. Weight variation can reveal a filling problem, but sample size and limits come from an applicable monograph, validated master formulation, or facility SOP. USP <795> does not impose a blanket “10 capsules within ±10%, none beyond ±15%” rule on every compounded capsule.
Containers
Check closure engagement, leakage, pump or syringe function, dosing-device compatibility, tamper evidence when applicable, and child-resistant packaging or documented exception under law. Ensure an oral product cannot be mistaken for a parenteral product.
- Calculations Used in QC
- Percent Yield
- Percent yield = actual final yield / theoretical yield × 100
If theoretical yield is 40.0 g and actual yield is 38.6 g:
38.6 / 40.0 × 100 = 96.5%
The arithmetic does not establish acceptability. Compare 96.5% with the master-formulation or process specification and investigate unexplained loss. A 95–105% range may be a stated facility criterion for one formulation, but it is not a universal USP release range.
- Weight Deviation
- Weight deviation (%) = |individual weight − target weight| / target weight × 100
Use the target, sample plan, and acceptance rule specified for that formulation. Weight is a surrogate for content only when fill composition and mixing uniformity justify the inference; it does not directly assay potency.
Potency
USP <795> uses 90–110% of labeled strength as the general CNSP strength expectation unless an applicable monograph establishes another range. A specific formulation may require a narrower specification. Potency testing must use a suitable method capable of measuring the API in the actual matrix; physical inspection cannot establish potency.
pH, Density, and Microbial Testing
Select objective tests from formulation risk and specification:
Test Purpose Acceptance source
pH Stability, solubility, preservative performance, route compatibility Master formulation, monograph, stability data
- Density/specific gravity Concentration and volumetric or fill control Validated formulation/SOP
- Potency assay Quantify active strength <795> expectation, monograph, formulation specification
- Microbial limits Evaluate microbial quality when indicated Applicable USP chapters, formulation and route
Antimicrobial effectiveness Support preserved aqueous formulation or extended BUD USP <51> and <795> BUD framework
Ophthalmic preparations are sterile preparations governed by <797>, so do not treat “ophthalmic” as an ordinary nonsterile pH-testing example.
MFR-to-CR Audit
Compare the Master Formulation Record (MFR) with the actual Compounding Record (CR) :
- component names, forms, manufacturers, lots, expiration dates, and actual quantities;
- calculations, scale-up or overage, and independent checks;
- equipment IDs and required verification status;
- sequence, time, temperature, mixing, transfer, and deviations;
- actual yield, inspection, test results, and container;
- label, storage, BUD source and calculation;
compounder and verifier identities and release authorization.
If a deviation could affect quality, quarantine the CNSP until the designated person completes an impact assessment and disposition.
Exam Decision Pattern
Calculate the requested value first, then compare it with the stated specification. If the question supplies no acceptance limit, do not invent one. Physical separation, wrong identity, a calculation mismatch, an unsupported BUD, or incomplete traceability requires hold and investigation.
- Quality Control Verification and Product Release Workflow MFR + Prescription + Applicable Specification
- │
- ▼
- CR traceability and calculation audit
- │
- ▼
- Physical inspection + required tests + yield/count
- │
- ├── Meets all criteria → authorized release
- └── Deviation/OOS → quarantine → investigate → disposition